COMP <GO>
PRFX vs APVO // RETURN ON INVESTED CAPITAL (ROIC)
PRF Technologies Ltd. (NASDAQ) VS. Aptevo Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRFX 3
— APVO 0
■ METRIC PARITY
LAST: $0.75 (-3.86%) • MKT CAP: $2.6M
roic
-35.00%
LAST: $1.36 (+4.62%) • MKT CAP: $2.5M
roic
-35.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRFX VS. APVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRFX | APVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | -30.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | PRFX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.6 | 26.9 | +9.72 | PRFX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.6M | $2.5M | $174.4K | PRFX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRFX REV | APVO REV | PRFX GROSS % | APVO GROSS % | PRFX FCF | APVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.0K | $0 | -50.0% | — | -$4.0M | -$25.6M |
| FY 2024 | $0 | $0 | — | — | -$12.6M | -$23.8M |
| FY 2023 | $0 | $0 | — | — | -$6.7M | -$11.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRFX // BETA —
APVO // BETA —